QQQ

DIA

SPY

TLT

GLD

BTC/USD

QQQ

DIA

SPY

TLT

GLD

BTC/USD

Range

33.5 - 35.51

Vol / Avg.

905.2K/766.7K

Div / Yield

-

52 Wk

33.5 - 56.4

Mkt Cap

4.8B

Payout Ratio

-

Open

35.05

P/E

12.13

EPS

1.53

Shares

140.8M

Outstanding

140.8M

Total Float

120.9M

Analyst Ratings

Wells Fargo Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $58

Benzinga - 3 days ago

Halozyme's Q3 Sales Boosted By Darzalex; Lifts FY21 Earnings Outlook

Benzinga - Nov 3, 2021, 11:42AM

JMP Securities Maintains Market Outperform on Halozyme Therapeutics, Raises Price Target to $55

Benzinga - Nov 3, 2021, 7:53AM

SVB Leerink Maintains Outperform on Halozyme Therapeutics, Lowers Price Target to $48

Benzinga - Nov 3, 2021, 7:34AM

UPDATE: Halozyme Therapeutics Q3 Adj. EPS $0.55 Beats $0.42 Estimate, Sales $115.83M Beat $101.94M Estimate

Benzinga - Nov 2, 2021, 5:53PM

Halozyme Therapeutics Raises EPS Guidance From $1.85-$2.00 To $1.90-$2.00, Raises Sales Guidance From $425M-$445M To $430M-$445M

Benzinga - Nov 2, 2021, 4:29PM

Halozyme Therapeutics Q3 EPS $1.48 Up From $0.25 YoY, Sales $115.83M Beat $101.94M Estimate

Benzinga - Nov 2, 2021, 4:27PM

Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS and sales results and raised FY21 EPS and sales guidance above estimates.

Benzinga - Aug 10, 2021, 8:36AM

Halozyme Stock Gains As Q2 Earnings Top Estimates On Higher Milestone, Royalty; Lifts FY21 Guidance

Benzinga - Aug 10, 2021, 6:51AM

Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS and sales results and raised FY21 EPS and sales guidance above estimates.

Benzinga - Aug 9, 2021, 4:19PM

UPDATE: Halozyme Raises FY21 Guidance: Sales From $375M-$395M To $425M-$445M vs $404.6M Estimate, Adj. EPS From $1.55-$1.70 To $1.85-$2 vs $1.41 Est.

Benzinga - Aug 9, 2021, 4:04PM

Halozyme Therapeutics Q2 Adj. EPS $0.66 Beats $0.40 Estimate, Sales $136.50M Beat $103.16M Estimate; Raises Guidance

Benzinga - Aug 9, 2021, 4:04PM

Janssen's Darzalex Faspro Wins FDA Approval In Combination With Pomalidomide, Dexamethasone For Multiple Myeloma

Benzinga - Jul 12, 2021, 9:09AM

Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO In Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse

Benzinga - Jul 12, 2021, 8:14AM

Halozyme Announces Janssen Receives European Marketing Authorizations For DARZALEX (daratumumab) Subcutaneous Formulation For Newly Diagnosed Systemic Light-Chain Amyloidosis And Pre-Treated Multiple Myeloma

Benzinga - Jun 22, 2021, 1:49PM

GSK- Pfizer's ViiV To Develop 'Ultra-Long-Acting' HIV Drugs With $215M Halozyme Deal

Benzinga - Jun 22, 2021, 6:29AM

ViiV Healthcare, Halozyme Enter Global Collaboration and License Agreement for ENHANZE Drug Delivery Technology to Enable Development of Ultra-long-acting Medicines for HIV

Benzinga - Jun 22, 2021, 5:12AM

Evercore ISI Group Initiates Coverage On Halozyme Therapeutics with Outperform Rating

Benzinga - Jun 14, 2021, 8:50AM

Halozyme Highlights Data Presentations By Collaborators For Therapies Utilizing ENHANZE At 2021 American Society Of Clinical Oncology Annual Meeting

Benzinga - Jun 1, 2021, 4:18PM

Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX Subcutaneous Formulation Utilizing ENHANZE

Benzinga - May 21, 2021, 10:03AM

load more

Sector: Health Care.Industry: Biotechnology

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Earnings

Q4 2021		Est.		Actual		Surprise
EPS		(EXPECTED)2022-02-22
REV		(EXPECTED)2022-02-22

Q3 2021		Est.		Actual		Surprise
EPS		0.420		0.550		0.1300
REV		101.940M		115.830M		13.890M

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Halozyme Therapeutics Questions & Anwsers

Q

How do I buy Halozyme Therapeutics (HALO) stock?

A

You can purchase shares of Halozyme Therapeutics (NASDAQ: HALO) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Halozyme Therapeutics's (HALO) competitors?

A

Other companies in Halozyme Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), Ultragenyx Pharmaceutical (NASDAQ:RARE), Sarepta Therapeutics (NASDAQ:SRPT), Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Karuna Therapeutics (NASDAQ:KRTX).

Q

What is the target price for Halozyme Therapeutics (HALO) stock?

A

The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by Wells Fargo on November 24, 2021. The analyst firm set a price target for 58.00 expecting HALO to rise to within 12 months (a possible 71.34% upside). 7 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Halozyme Therapeutics (HALO)?

A

The stock price for Halozyme Therapeutics (NASDAQ: HALO) is $33.85 last updated Fri Nov 26 2021 18:00:03 GMT+0000 (Coordinated Universal Time).

Q

Does Halozyme Therapeutics (HALO) pay a dividend?

A

There are no upcoming dividends for Halozyme Therapeutics.

Q

When is Halozyme Therapeutics (NASDAQ:HALO) reporting earnings?

A

Halozyme Therapeutics’s $Q4 earnings are confirmed for after-market on February 22, 2022.

Q

Is Halozyme Therapeutics (HALO) going to split?

A

There is no upcoming split for Halozyme Therapeutics.

Q

What sector and industry does Halozyme Therapeutics (HALO) operate in?

A

Halozyme Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.